Wikipedia -WSS

Wikipedia

author：hotspot 2025-09-28 07:01:34 - browse：931

The future looks even brighter for the blockbuster Enhertu, showcased here at ASCO. ADAM FEUERSTEIN/STAT

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a year, significantly longer than standard chemotherapy did in women with the most common form of metastatic breast cancer — a clinical trial result that once again promises to rewrite the rules for the treatment of the disease.

The makers of Enhertu, Daiichi Sankyo and AstraZeneca, said the new data, if cleared by regulators, could shift the way physicians treat hormone receptor-positive, metastatic breast cancer, and create a new standard of care in which patients with breast tumors that express even the faintest amount of HER2 protein can benefit.

“It’s not an overestimation to say that trastuzumab deruxtecan is the most potent drug ever developed for breast cancer,” said Paolo Tarantino, a medical oncologist at the Dana-Farber Cancer Institute, using the scientific name for Enhertu. “It does come with side effects that we’re learning to manage, but with that said, I’ve never seen data like what’s being reported here.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Why the drug industry's warnings on the IRA's impact fall short

focus

WSS

Senate bill would ban some hospital facility fees

First transplant of an entire human eye performed

Chamber of Commerce, DOJ clash in court over drug prices

How state and local governments are sidelining science

Healthy food access boosts outcomes in two studies

Type 2 diabetes prevention programs work at large scale: study

hotspot

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Affirmative action in medical school literally saved lives

Publishing genetic code of viruses could cause disaster

At least 13 dead in Texas as scorching temps continue

What health policies could hitch a ride on a spending bill?

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Experimental asthma app from Apple and Anthem shows promise

As demand for Covid shots wanes, Moderna seeks its next success

Medicare’s new pay boost for primary care is angering specialists

Malaria cases in Florida and Texas: Here’s what you need to know

Readout Newsletter: Zepbound, Valneva's vaccine, and more

leisure time

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Study suggests Covid rebound is far more common with Paxlovid than without

Midwives could help bridge maternal health disparities in the U.S.

How state and local governments are sidelining science

Why the drug industry's warnings on the IRA's impact fall short

What is STAT's opinion section for?

hotspot

focus

focus

Wikipedia